Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil
- PMID: 6608049
Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil
Abstract
The purpose of this study was to compare the pools of free FdUMP derived from 5-fluorouracil (FUra) and of dUMP synthesized de novo in Hep-2 and S-180 cells, their relationship to inhibition of thymidylate synthase (dTMP synthase; EC 2.1.1.45), and the effect of excess folinic acid (CF) on these parameters. These cells differ 50-fold in their sensitivity to FUra and, in the absence of thymidine, dTMP synthase is the growth-limiting site of action of FUra in S-180 cells, but in Hep-2 cells this site becomes growth-limiting only in the presence of excess folates. In both cells after a 3-hr incubation with varied concentrations of FUra, FdUMP comprised only 0.1-0.2% of the total acid-soluble pools derived from FUra. The changes in dUMP and FdUMP pools paralleled each other, dUMP being 1000-2000 times higher than FdUMP. The pools of dUMP increased only when dTMP synthase was significantly inhibited. This occurred in S-180 cells above 3 microM FUra and in Hep-2 cells above 30 microM, where the residual dTMP synthase was similar in both cells. Under these conditions, the dUMP and FdUMP pools in Hep-2 cells were 2 and 4 times higher, respectively, than in S-180 cells. After FUra removal, both pools continued to increase, dUMP and FdUMP pools in Hep-2 cells rising 6-fold and 10-fold higher, respectively, than in S-180 cells. The dTMP synthase inhibition and the high nucleotide pools in Hep-2 were short-lived, whereas in S-180 cells the inhibition and the pools were maintained longer. Excess CF retarded the recovery of dTMP synthase after FUra removal only in Hep-2 cells and led to a further increase in dUMP and FdUMP pools in these cells, while having no effect in S-180 cells. These data indicate that a high capacity of cells to accumulate free FdUMP does not alone guarantee that dTMP synthase inhibition will be growth-limiting. The relationship shown here between excess CF, dTMP synthase recovery, and the nucleotide pools suggests that some cell types, such as Hep-2, in spite of high levels of FdUMP, require in addition an excess of folates to retard dTMP synthase recovery and make it growth-limiting.
Similar articles
-
Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.Oncol Res. 1997;9(2):77-88. Oncol Res. 1997. PMID: 9167189
-
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.Cancer Res. 1988 Oct 15;48(20):5894-900. Cancer Res. 1988. PMID: 3167844
-
Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.J Clin Invest. 1975 Nov;56(5):1231-8. doi: 10.1172/JCI108199. J Clin Invest. 1975. PMID: 1184747 Free PMC article.
-
Molecular mechanism of thymidylate synthase-catalyzed reaction and interaction of the enzyme with 2- and/or 4-substituted analogues of dUMP and 5-fluoro-dUMP.Acta Biochim Pol. 1996;43(1):133-42. Acta Biochim Pol. 1996. PMID: 8790719 Review.
-
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. doi: 10.1016/s0925-4439(02)00082-0. Biochim Biophys Acta. 2002. PMID: 12084461 Review.
Cited by
-
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.Invest New Drugs. 2004 Nov;22(4):467-73. doi: 10.1023/B:DRUG.0000036689.28596.c6. Invest New Drugs. 2004. PMID: 15292717 Clinical Trial.
-
Kinetic analysis of 5-fluorouracil action against various cancer cells.Jpn J Cancer Res. 1990 Oct;81(10):1039-44. doi: 10.1111/j.1349-7006.1990.tb03343.x. Jpn J Cancer Res. 1990. PMID: 2146239 Free PMC article.
-
Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.Cancer Chemother Pharmacol. 1994;35(2):109-14. doi: 10.1007/BF00686631. Cancer Chemother Pharmacol. 1994. PMID: 7987985
-
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.Br J Clin Pharmacol. 1994 Mar;37(3):243-8. doi: 10.1111/j.1365-2125.1994.tb04270.x. Br J Clin Pharmacol. 1994. PMID: 8198932 Free PMC article. Clinical Trial.
-
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.Cancer Chemother Pharmacol. 2017 Jun;79(6):1077-1085. doi: 10.1007/s00280-017-3295-8. Epub 2017 Apr 17. Cancer Chemother Pharmacol. 2017. PMID: 28417167 Free PMC article.